[SCIENTX] QoQ TTM Result on 31-Jan-2021 [#2]

Stock
[SCIENTX] SCIENTEX BERHAD
Announcement Date
09-Mar-2021
Admission Sponsor
-
Sponsor
-
Financial Year
31-Jul-2021
Quarter
31-Jan-2021 [#2]
Profit Trend
QoQ- 3.66%
YoY- 8.23%
Quarter Report
Latest QR
Upcoming QR
SCIENTX's Result
SCIENTX's Financial Summary
View:
Show?
TTM Result
31/10/21 31/07/21 30/04/21 31/01/21 31/10/20 31/07/20 30/04/20 CAGR
Revenue 3,781,879 3,655,966 3,640,231 3,435,662 3,443,495 3,518,601 3,502,737 5.22%
PBT 603,350 600,961 610,640 566,480 556,448 544,262 536,647 8.10%
Tax -109,263 -115,185 -124,272 -120,668 -125,980 -126,236 -128,805 -10.36%
NP 494,087 485,776 486,368 445,812 430,468 418,026 407,842 13.60%
-
NP to SH 467,574 457,233 456,631 416,377 401,685 390,114 381,464 14.49%
-
Tax Rate 18.11% 19.17% 20.35% 21.30% 22.64% 23.19% 24.00% -
Total Cost 3,287,792 3,170,190 3,153,863 2,989,850 3,013,027 3,100,575 3,094,895 4.10%
-
Net Worth 2,930,741 2,899,651 2,806,576 2,698,034 2,658,038 2,563,907 2,434,938 13.11%
Dividend
31/10/21 31/07/21 30/04/21 31/01/21 31/10/20 31/07/20 30/04/20 CAGR
Div 139,554 139,554 129,087 118,651 118,651 118,651 103,113 22.28%
Div Payout % 29.85% 30.52% 28.27% 28.50% 29.54% 30.41% 27.03% -
Equity
31/10/21 31/07/21 30/04/21 31/01/21 31/10/20 31/07/20 30/04/20 CAGR
Net Worth 2,930,741 2,899,651 2,806,576 2,698,034 2,658,038 2,563,907 2,434,938 13.11%
NOSH 1,550,656 1,550,656 1,550,594 1,550,594 516,864 515,876 515,876 107.86%
Ratio Analysis
31/10/21 31/07/21 30/04/21 31/01/21 31/10/20 31/07/20 30/04/20 CAGR
NP Margin 13.06% 13.29% 13.36% 12.98% 12.50% 11.88% 11.64% -
ROE 15.95% 15.77% 16.27% 15.43% 15.11% 15.22% 15.67% -
Per Share
31/10/21 31/07/21 30/04/21 31/01/21 31/10/20 31/07/20 30/04/20 CAGR
RPS 243.89 235.78 234.76 221.57 667.18 682.06 678.99 -49.37%
EPS 30.15 29.49 29.45 26.85 77.83 75.62 73.94 -44.92%
DPS 9.00 9.00 8.33 7.65 23.00 23.00 20.00 -41.19%
NAPS 1.89 1.87 1.81 1.74 5.15 4.97 4.72 -45.58%
Adjusted Per Share Value based on latest NOSH - 1,550,594
31/10/21 31/07/21 30/04/21 31/01/21 31/10/20 31/07/20 30/04/20 CAGR
RPS 243.01 234.92 233.91 220.76 221.27 226.09 225.07 5.23%
EPS 30.04 29.38 29.34 26.75 25.81 25.07 24.51 14.48%
DPS 8.97 8.97 8.29 7.62 7.62 7.62 6.63 22.25%
NAPS 1.8832 1.8632 1.8034 1.7337 1.708 1.6475 1.5646 13.11%
Price Multiplier on Financial Quarter End Date
31/10/21 31/07/21 30/04/21 31/01/21 31/10/20 31/07/20 30/04/20 CAGR
Date 29/10/21 30/07/21 30/04/21 29/01/21 30/10/20 30/07/20 30/04/20 -
Price 4.66 4.18 4.19 3.99 11.88 9.10 8.30 -
P/RPS 1.91 1.77 1.78 1.80 1.78 1.33 1.22 34.71%
P/EPS 15.45 14.18 14.23 14.86 15.26 12.03 11.22 23.70%
EY 6.47 7.05 7.03 6.73 6.55 8.31 8.91 -19.16%
DY 1.93 2.15 1.99 1.92 1.94 2.53 2.41 -13.72%
P/NAPS 2.47 2.24 2.31 2.29 2.31 1.83 1.76 25.27%
Price Multiplier on Announcement Date
31/10/21 31/07/21 30/04/21 31/01/21 31/10/20 31/07/20 30/04/20 CAGR
Date 08/12/21 29/09/21 23/06/21 09/03/21 17/12/20 18/09/20 23/06/20 -
Price 4.58 4.57 4.26 4.00 12.02 9.50 8.77 -
P/RPS 1.88 1.94 1.81 1.81 1.80 1.39 1.29 28.45%
P/EPS 15.19 15.50 14.47 14.90 15.44 12.56 11.86 17.88%
EY 6.58 6.45 6.91 6.71 6.47 7.96 8.43 -15.18%
DY 1.97 1.97 1.95 1.91 1.91 2.42 2.28 -9.25%
P/NAPS 2.42 2.44 2.35 2.30 2.33 1.91 1.86 19.12%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment